Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial

Phase 1positiveAVA6103Positive

AI Analysis

Summary

Avacta Therapeutics announced positive Phase 1 data for AVA6103 (FAP-Exd), achieving clinical proof of mechanism for its next-generation pre|CISION peptide-drug conjugate platform in the FOCUS-01 trial.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

achieved clinical proof of mechanism

Importance:6/10

Sentiment:

0.75

oncologyPDC platformpre|CISIONcontrolled-releaseproof of mechanism

Related Companies

$AVCT.L

Read the original article

Published by GlobeNewswire Clinical Studies on September 16, 2026 3:00 PM

Read Original